

Amendments to the Claims:

Please amend the claims to read as follows:

1. - 3. (Cancelled)

4. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~2~~11 wherein the therapeutically effective amount the extract of *Uncaria tomentosa* is obtained from a commercially available source.

5. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim 4 wherein the commercially available source of *Uncaria tomentosa* is selected from the group consisting of pills, tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixers, suspensions, emulsions, solutions, syrups, tea bags, aerosols ~~(as a solid or in a liquid medium)~~, suppositories, sterile injectable solutions, sterile packaged powders, bark bundles ~~or~~and bark powder.

6. (Cancelled)

7. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~2~~11 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.

8. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim 7 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.

9. (Cancelled)

10. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~9~~11 wherein ~~said~~the amyloid disease ~~for treatment~~ is Alzheimer's Disease.

11. (Currently Amended) ~~The~~A ~~pharmaceutical agent of claim 3 for treating an amyloid disease in a patient, wherein the agent comprises a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus *Uncaria*, species *tomentosa*, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.~~

12. (Re-presented and amended) The pharmaceutical agent of claim ~~11~~ further comprising a pharmaceutically acceptable carrier, diluent or excipient.

13. (Re-presented and amended) The pharmaceutical agent of claim ~~211~~ wherein the therapeutically effective amount of ~~plant matter~~the extract has an amyloid inhibitory activity or efficacy greater than 50%.

14.-47. (Cancelled)

48. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~4652~~ wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.

49. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim 48 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.

50. (Cancelled)

51. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~5052~~ wherein ~~said~~the amyloid disease ~~for treatment~~ is Alzheimer's Disease.

52. (Currently Amended) ~~The~~A pharmaceutical agent of claim ~~46~~comprising a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus *Uncaria*, species *tomentosa*, the therapeutic amount of the extract selected for efficacy in treating an amyloid disease in a patient, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.

53. (Re-presented and amended) The pharmaceutical agent of claim ~~4652~~ further comprising a pharmaceutically acceptable carrier, diluent or excipient.

54. (Re-presented and amended) The pharmaceutical agent of claim ~~4652~~ wherein the therapeutically effective amount of ~~plant matter~~extract has an amyloid inhibitory activity or efficacy greater than 50%.

Respectfully submitted,

P07-revAmd.RSP



PATRICK MICHAEL DWYER
Reg. No. 32,411

PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109